Postoperative combined radiation and chemotherapy improves disease-free survival (DFS) and overall survival (OS) in resected adenocarcinoma of the stomach and G.E. junction. Results of intergroup study INT-0116 (SWOG 9008)

MacDonald, Julie; Smalley, Stephen R.; Benedetti, Jacqueline; Hundahl, Scott A.; Estes, Norman C.; Stemmermann, G.N.; Haller, D.G.; Ja, Ajani; Gunderson, L. L.; Jessup, Marsha

doi:10.1016/s0959-8049(01)80526-8

Cited by 96 publications

(91 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Many studies have been conducted to elucidate the effectiveness of other treatment modalities. In the USA adjuvant radiotherapy is given according to the SWOG-trial, 28 and in the East an extended lymphadenectomy is performed. In our country, standard care for curable disease, until recently, consisted of gastric resection without (neo)adjuvant therapy, 29 although in more recent years more patients are treated with chemotherapy as reflected in our results.…”

Section: Discussionmentioning

confidence: 99%

Trends in incidence, treatment and survival of gastric adenocarcinoma between 1990 and 2007: A population-based study in the Netherlands

Dassen¹,

Lemmens²,

Poll‐Franse³

et al. 2010

European Journal of Cancer

131

View full text Add to dashboard Cite

General rightsCopyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.-Users may download and print one copy of any publication from the public portal for the purpose of private study or research -You may not further distribute the material or use it for any profit-making activity or commercial gain -You may freely distribute the URL identifying the publication in the public portal Take down policyIf you believe that this document breaches copyright, please contact us providing details, and we will remove access to the work immediately and investigate your claim. Conclusion:The absence of improvement in survival rates indicates the need for earlier detection and prospective studies to evaluate new therapy regimens with standardised surgery and pathology.

show abstract

Section: Discussionmentioning

confidence: 99%

Trends in incidence, treatment and survival of gastric adenocarcinoma between 1990 and 2007: A population-based study in the Netherlands

Dassen¹,

Lemmens²,

Poll‐Franse³

et al. 2010

European Journal of Cancer

131

View full text Add to dashboard Cite

show abstract

“…This study failed to demonstrate a survival benefit and reported an objective response rate of only 10% [34]. Other non-randomized trials using 5-FU chemotherapy alone or in combination with other chemotherapy agents infused systemically or locally have reported non-statistically significant improvements compared with surgery alone 17,35 . Park et al 36 in retrospective study reported that overall survival (OS) was not significantly different among the adjuvant therapies (P = 0.180), but disease-free survival (DFS) was (P = 0.033).…”

mentioning

confidence: 71%

A Review of Recent Data in the Treatment of Gallbladder Cancer

Shah

Qari²,

Altaf

et al. 2016

Bangladesh J Med Sci

View full text Add to dashboard Cite

Abstract:Gallbladder cancer is now considered a distinct clinical entity, allowing for a separate analysis from that of other malignancies of the biliary tree. Symptoms related to a malignant tumor of the gallbladder include jaundice and abdominal pain, or a palpable abdominal mass that occurs in a late stage of the disease. The majority of patients with operable gallbladder cancer are diagnosed by cholecystectomy performed for presumed benign disease, mostly cholelithiasis, a clinical entity known as incidental gallbladder cancer. Given the poor prognosis if tumor invasion beyond the muscular layer and/or nodal metastasis is found, adjuvant treatments have been implemented, but few data are available to guide treatment decisions in this setting. For advanced disease, a multidisciplinary treatment approach including biliary drainage procedures and palliative support is needed in the management of this aggressive disease. Palliative chemotherapy with a combination of gemcitabine and cisplatin or oxaliplatin is the standard treatment based on the findings of two phase III trials that showed improved overall survival compared to single-agent chemotherapy and best supportive care. Several phase II studies have been reported investigating the role of targeted agents against EGFR, VEGF, HER2, and MEK. International collaboration to enhance our knowledge of gallbladder cancer should be encouraged.

show abstract

“…Thus, the INT 0116 study published in 2001, was the pivotal randomized trial compared 2 arms: surgery associated or not to combined chemoradiation [11]: At 3 year PFS was 41% in the surgery arm alone and 50% in adjuvant CCR arm (p<0.001); 3 years OS was 41% in the surgery arm alone and 48% in adjuvant therapy arm (p=0.005) [11]. The update of the intergroup trial was confirmed the OS benefit at 10 years [13]. These results have been confirmed by other authors [12,14,15].…”

Section: Discussionmentioning

confidence: 92%

Adjuvant Chemoradiation for Localized Gastric Adenocarcinoma: An Institutional Experience

Touil¹,

Loughlimi²,

Abbassi³

et al. 2017

J Cancer Sci Ther

View full text Add to dashboard Cite

BackgroundGastric cancer is the second leading cause of cancer related death among men and the fourth among women, and thus represents a significant global health concern [1]. The disease is commonly diagnosed at a locally advanced stage, and surgery remains the main treatment; The overall survival rate of patients who underwent surgery alone is about 45% at 5 years, that has undergone few changes over the last decades [2,3].The curative treatment of gastric cancer requires surgical resection in less than 40% of cases [2,3]. Independent risk factors in the literature are tumor size (>4 cm), age (>70 years), proximal location, diffuse type of Lauren classification, tumor residue, Deep invasion (T3-T4), and the ratio of involved lymph nodes/total number (>20%) [4,5]. Locoregional recurrences on the tumor bed, on the anastomosis or in lymph nodes occur in 40% to 65% of the patients after resection with curative intent [6,7]. The frequency of this relapse makes regional radiotherapy an attractive possibility for adjuvant therapy [8].Various chemotherapy regimens used to prevent relapse and improve the poor survival rates provide small but statistically significant clinical benefit [9,10]. Finally, the intergroup of gastrointestinal cancers was the first to demonstrate in a phase III trial that concomitant radio-chemotherapy after complete gastric resection improves median relapse-free survival (30 vs 19 months, p<0.0001) and overall survival (36 vs 27 months, p<0.01) [11]. Following these results, postoperative radio-chemotherapy according to the Macdonald protocol became the new standard of care [11]. However, much concern remains regarding the toxicity of the regimen. 41% of patients had grade 3 digestive toxicity and 32% grade 4 [11]. The objective of our AbstractBackground: Several studies have shown that surgery alone is not enough in the management of early gastric cancer with locoregional relapse in 40% to 60%. The frequency of relapses makes regional radiotherapy an attractive possibility for adjuvant therapy. The survival benefit of adjuvant chemoradiation over surgery alone was first established by the US Intergroup 0116 study.

show abstract

Postoperative combined radiation and chemotherapy improves disease-free survival (DFS) and overall survival (OS) in resected adenocarcinoma of the stomach and G.E. junction. Results of intergroup study INT-0116 (SWOG 9008)

Cited by 96 publications

References 0 publications

Trends in incidence, treatment and survival of gastric adenocarcinoma between 1990 and 2007: A population-based study in the Netherlands

Trends in incidence, treatment and survival of gastric adenocarcinoma between 1990 and 2007: A population-based study in the Netherlands

A Review of Recent Data in the Treatment of Gallbladder Cancer

Adjuvant Chemoradiation for Localized Gastric Adenocarcinoma: An Institutional Experience

Contact Info

Product

Resources

About